Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Watson buys Andrx for $1.9bn

Executive Summary

Specialty pharmaco Watson will acquire Andrx (develops generic products using its drug delivery technologies) for about $1.9bn in cash, creating a top- three US generics company. The deal is expected to close in the third quarter of 2006, after which Andrx becomes a wholly owned subsidiary.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Cash
    • Full Acquisition
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register